GATT Technologies: A Game-changing Solution for Complex Surgical Bleeding
Geert van Gansewinkel, CEO
Surgical bleeding is a critical challenge in operating rooms even today. Traditional methods to treat bleeding include application of pressure and suturing, but in case this fails, use of hemostats and sealants assists surgeons with achieving hemostasis. However, these existing hemostatic solutions have low adhesion and sealing properties and a long time to hemostasis. They require long pressure time (up to 3-6 minutes), costing surgeons’ valuable time in the operating room. This can lead to rebleeding and excessive blood loss resulting inthe need for reoperation or postoperative blood transfusion, infection, impaired wound healing, and even mortality. Recognizing this unmet need in managing complex surgical bleeding, Johan Bender, a surgical care veteran, incepted GATT Technologies in 2011. Leveraging its patented technology, the company has developed a platform that has already proven successful in controlling bleeding where conventional products are not effective. “Our platform is the next frontier of hemostats and sealants with fast hemostasis, strong adhesion, flexibility, and broader applications,” says Geert van Gansewinkel, CEO of GATT Technologies.
The revolutionary platform of GATT Technologies outperforms the current hemostatic and sealant solutions in the market with its unique advantages. Based on synthetic NHS-POx technology, the platform enables fast hemostasis and strong adhesion within seconds. The ability to tune its adhesiveness helps achieve optimal effectiveness for specific applications. This also allows different product formulations, enabling a complete hemostatic and sealant portfolio. Further, the use of low-cost synthetic ingredients and a production process that can be standardized facilitates cost-effective and scalable production, whilst improving surgical outcomes and reducing mortality. Another significant feature is that GATT will be expanding the market by providing solutions to complex bleeding situations that currently do not have strong alternatives. For instance, GATT’s solutions aim to enable effective hemostasis after partial resections using robots or laparoscopy. Due to the lack of hemostatic products and the resulting risk of bleeding issues, these procedures are mostly not performed today.
GATT’s platform is designed as a one-stop-shop solution to address gaps in the global hemostatic market. GATT-Patch is the first one going to market in the comprehensive suite of superior-quality hemostatic products.
Our platform is the next frontier of hemostats and sealants with fast hemostasis, strong adhesion, flexibility, and broader applications
As a sealing hemostatic patch for general surgery, GATT-Patch controls heavier to severe bleedings faster than the current alternatives in the market. GATT-Powder is another product specifically developed for laparoscopic and robotic use and will facilitate instant and easy-to-use application to control heavy bleeding cavities and will follow the indications of GATT-Patch. Further, the R&D pipeline consists of GATT-Spray for sealing procedures and GATT-Tape to prevent intestinal anastomotic leakage.
With GATT-Patch in the pre-clinical and planned testing stage, the enthusiastic response from surgeons emphasizes its potential success. “Our product has been very successful and effective compared to current products in various testing models, we are truly excited about its potential to be a game changer in this market,” remarks Gansewinkel.
Being a startup, GATT’s unique team is the real cornerstone for its groundbreaking achievements in hemostatic product development. The team brings a diverse experience mix in the fields of medicine, biochemistry, general life sciences, and clinical development. This has helped them to collaborate with academicians to develop the technology to what it is today. Bender, GATT’s founder and CTO, is heading the research and development of additional products in surgical care.
Having established itself as a technology-oriented company, GATT is now focusing on expanding its business globally. The company is managing operations, streamlining its supply chain, and ramping up marketing for growth. GATT is also dedicating its utmost diligence to quality and regulatory compliance, ensuring the safety of its solutions. With more than 20 years of experience in strategy consulting and general management, Gansewinkel is at the helm of steering the company to achieve expansion.
Moving ahead, GATT aims to release GATT Patch in the European market by Q2 2022. The company plans to develop solutions for complex surgeries, including liver, spleen, kidney, and pancreatic resections, as well as cardiovascular, lung, orthopedic, and neurosurgery utilizing its ramp-up strategy. GATT is also looking at other applications such as bones, dental, and trauma. With next-generation technology and innovative solutions, the company is indeed driving a future of better surgical care.
Description GATT Technologies has introduced a revolutionary platform that has already proven successful in controlling organ bleeding where conventional products are not effective. Based on synthetic NHS-POx technology, the platform is the next frontier of hemostats and sealants with fast hemostasis, strong adhesion, flexibility, and broader applications. The ability to tune its adhesiveness helps achieve optimal effectiveness for specific applications. Further, the use of low-cost synthetic ingredients and a production process that can be standardized facilitates cost-effective and scalable production, whilst improving surgical outcomes and reducing mortality
This content is copyright protected
However, if you would like to share the information in this article, you may use the link below: